This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	FMS-like tyrosine kinase 3 ligand (FLT3LG)	<p>Mouse studies suggest FLT3LG could help increase the potency of naked RNA vaccines. In a mouse model of melanoma, a naked RNA vaccine plus FLT3LG resulted in a 70% cure rate compared with 30% for vaccine alone. Next steps include evaluating the toxicity of the combination under Good Laboratory Practice conditions. At least 11 companies have FLT3 (CD135) inhibitors in Phase II testing or earlier to treat various cancers.</p> <p>SciBX 4(34); doi:10.1038/scibx.2011.960 Published online Sept. 1, 2011</p>	Patented; licensed to BioNTech AG	<p>Kreiter, S. <i>et al. Cancer Res.</i>; published online Aug. 4, 2011; doi:10.1158/0008-5472.CAN-11-0291 Contact: Ugur Sahin, Johannes Gutenberg University School of Medicine, Mainz, Germany e-mail: sahin@uni-mainz.de</p>